Indivior Pharmaceuticals (INDV) Stock News

Indivior (Nasdaq/LSE: INDV) has scheduled its second quarter 2025 financial results announcement for July 31, 2025 at 7:00 a.m. U.S. ET. Following the financial release, CEO Joe Ciaffoni and the leadership team will host a live webcast presentation at 8:00 a.m. U.S. ET.

Investors can access the webcast and presentation materials through the company's website at www.indivior.com. The event will also be accessible via telephone, with registration required for dial-in details. A replay of the presentation will be made available on the company's website afterward.

Indivior (NASDAQ/LSE: INDV) has appointed Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Procter brings 25 years of biopharmaceutical industry experience and will oversee Corporate Communications, Government Affairs, Policy and Advocacy.

Prior to joining Indivior, Procter served as Senior Vice President of Corporate Affairs at Sage Therapeutics, where she led the successful launch of ZURZUVAE™. She previously held leadership positions at Alexion Pharmaceuticals and MedImmune, and worked as a health policy advisor in the U.S. House of Representatives.

Indivior PLC (Nasdaq/LSE: INDV) announced its inclusion in the U.S. small-cap Russell 2000® Index and Russell 3000® Index, effective June 30, 2025. This inclusion is part of the 2025 Russell indexes reconstitution, which captures the 4,000 largest U.S. stocks based on market capitalization as of April 30.

The company highlighted that 85% of its net revenue in 2024 was generated in the U.S., primarily from SUBLOCADE®, their first-in-class, long-acting injectable medication for opioid use disorder treatment. The Russell indexes are significant benchmarks in the investment community, with approximately $10.6 trillion in assets benchmarked against U.S. Russell indexes as of June 2024.

Indivior PLC (NASDAQ/LSE: INDV) has appointed Tony Kingsley as an Independent Non-Executive Director to its Board, effective July 1, 2025. The appointment was supported by affiliates of Oaktree Capital Management. Kingsley, currently CEO of Stablix, Inc., brings extensive biopharmaceutical leadership experience, having previously served as CEO of Scholar Rock and TARIS Bio, and held senior roles at The Medicines Company and Biogen.

As an accomplished executive with expertise in commercial operations and clinical development, Kingsley will contribute to Indivior's mission of delivering treatments for opioid use disorder (OUD) and realizing the potential of SUBLOCADE®. His appointment strengthens Indivior's leadership in providing life-transforming OUD treatments.

Indivior (NASDAQ: INDV) presented new data at CPDD showing that higher doses (300mg) of SUBLOCADE, their buprenorphine extended-release treatment, may improve outcomes for opioid use disorder (OUD) patients with heavy fentanyl use. While not statistically significant compared to 100mg doses, the 300mg maintenance dose showed clinically meaningful improvements in opioid abstinence. Both dosing regimens demonstrated significant reductions in opioid use, from 40 instances weekly to fewer than 3 by Week 3, sustained through Week 38, with no new safety concerns. The company also presented research on treatment barriers for American Indian/Alaska Native populations, who face disproportionate OUD rates. A claims analysis of 75,000+ AI/AN patients revealed that 73.1% used non-IHS providers, and MOUD-treated patients showed lower emergency department visits.

Indivior PLC (INDV) has announced plans to cancel its secondary listing on the London Stock Exchange (LSE) while maintaining its primary Nasdaq listing, effective July 25, 2025. This strategic decision follows the company's transition to a U.S. primary listing and reflects that over 80% of revenue comes from the U.S. market, primarily driven by SUBLOCADE. The move is supported by key factors: approximately 75% of trading volume now occurs on Nasdaq, over 70% of shareholders are U.S.-based, and it will reduce costs and complexity of maintaining dual listings. The last trading day on LSE will be July 24, 2025. The UK Takeover Code will continue to apply for two years after delisting. The decision requires no shareholder approval and is expected to have no impact on direct holders of Ordinary Shares or those holding through DTC brokers.

Indivior PLC (Nasdaq/LSE: INDV) has appointed Patrick Barry as Chief Commercial Officer, effective June 2, 2025. Barry, a seasoned pharmaceutical executive with over 30 years of experience, will lead the company's commercial growth strategy and operations, focusing on advancing the treatment of opioid use disorder through SUBLOCADE®. Previously serving as executive vice president and chief commercial officer at Endo Pharmaceuticals, Barry managed commercial activities across three U.S. business segments with approximately $2 billion in revenue. His extensive career includes over two decades at Sanofi in various senior leadership positions. Barry holds an MBA from Cornell University and will join Indivior's executive committee.

Indivior PLC (NASDAQ/LSE: INDV) has announced its participation in three major investor events in June 2025. CEO Joe Ciaffoni and CFO Ryan Preblick will attend:

1. Jefferies Global Healthcare Conference in New York City on June 4th, featuring 1x1/group meetings and a fireside discussion at 9:55 a.m. ET (publicly available via webcast)

2. Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 11th, hosting 1x1/group meetings

3. Northland Growth Conference 2025, a virtual event on June 25th, conducting 1x1/group meetings

Interested investors need to contact their respective conference representatives to schedule meetings.

Indivior PLC (INDV) announced a groundbreaking study on SUBLOCADE®, their monthly buprenorphine depot injection for treating opioid use disorder (OUD) during pregnancy. The study, published in the American Journal on Addictions, analyzed data from three sources: clinical case studies of four pregnant patients, five-year postmarketing surveillance data covering 322 pregnancy exposures, and a targeted literature review. Key findings showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates. All four patients in the clinical case studies delivered healthy, full-term infants with normal birthweight and no neonatal opioid withdrawal syndrome. This research is particularly significant as opioid use during pregnancy increased 131% between 2010-2017, with pregnancy-related overdose deaths involving fentanyl rising from 5.73 to 9.47 per 100,000 from 2017-2020.